Results 81 to 90 of about 32,698 (277)

Borrelia crocidurae Infection in Acutely Febrile Patients, Senegal

open access: yesEmerging Infectious Diseases, 2014
As malaria cases in Africa decline, other causes of acute febrile illness are being explored. To determine incidence of Borrelia crocidurae infection during June 2010–October 2011, we collected 1,566 blood specimens from febrile patients in Senegal ...
Oleg Mediannikov   +7 more
doaj   +1 more source

Small mammals tested for anti-relapsing fever spirochete antibodies.

open access: yes, 2012
Small mammals tested for anti-relapsing fever spirochete antibodies.
Robert J. Fischer (119335)   +9 more
core   +1 more source

Efficacy, safety and cost‐effectiveness of CAR‐T therapy

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
CAR T‐cells demonstrate high efficacy in blood cancers, including ALL, MM and DLBCL. Innovations target solid tumours despite challenges such as antigen escape. Combination therapies enhance the delivery and infiltration of CAR T cells. Toxicity, cost and resistance remain major barriers to clinical use.
Emina Karahmet Sher   +7 more
wiley   +1 more source

Louse-borne relapsing fever (Borrelia recurrentis) in asylum seekers from Eritrea, the Netherlands, July 2015 [PDF]

open access: yes, 2015
Two patients from Eritrea, recently arrived in the Netherlands, presented with fever and were investigated for malaria. Bloodfilms showed spirochetes but no blood parasites.
Sinha, B.; id_orcid   +6 more
core   +1 more source

Oligonucleotides used for PCR and MLST of relapsing fever spirochetes, Texas, USAb'*'.

open access: yes, 2021
Oligonucleotides used for PCR and MLST of relapsing fever spirochetes, Texas, USAb'*'.
Brittany A. Armstrong (5904665)   +10 more
core   +1 more source

Evaluating the (comparative) safety profile of the novel oral polio vaccine type 2 using individual case safety reports in VigiBase

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aim Novel oral polio vaccine type 2 (nOPV2) was used under the WHO emergency use listing for circulating vaccine‐derived polio virus (cVDPV) outbreaks from 2021 to 2023. We assessed nOPV2 adverse events following immunization (AEFIs) and compared its safety profile to other vaccines using VigiBase.
Comfort Kunak Ogar   +6 more
wiley   +1 more source

Tickborne Relapsing Fever, Bitterroot Valley, Montana, USA

open access: yes, 2015
In July 2013, a resident of the Bitterroot Valley in western Montana, USA, contracted tickborne relapsing fever caused by an infection with the spirochete Borrelia hermsii.
Sandra J. Raffel   +4 more
core   +1 more source

Biomaterial design strategies for enhancing mitochondrial transplantation therapy

open access: yesBMEMat, EarlyView.
Biomaterials to facilitate mitochondrial transplantation therapy: biomaterials as barriers to protect mitochondria from pathophysiological microenvironments, like osmotic stress caused by the excessive concentration of calcium ion, reactive oxygen species, and advanced glycation end products; biomaterials integrating with biochemical cues to improve ...
Shaoyang Kang   +12 more
wiley   +1 more source

Forgotten diseases: relapsing fever

open access: yes, 2019
Relapsing fever is a group of conditions that is characterized by recurrent febrile episodes interspaced with periods of no symptoms at all. They are arthropod-borne spirochetal infections of the Borrellia genus and occur in two main forms: tick-borne ...
Gangaidzo, I.T.
core  

Transition Metal Compounds as Thermochromic Materials: Classification, Properties, Limitations, and Applications

open access: yesEcoEnergy, EarlyView.
This review systematically examines how different transition metal compounds—such as binary and multinary metal oxides, halides, sulfides, and salts—exhibit thermochromism based on the d‐electron configurations of their transition metal cations. It focuses on three main mechanisms of thermochromism: phase transition, charge transfer, and bandgap change.
Jie Wang   +5 more
wiley   +1 more source

Home - About - Disclaimer - Privacy